Suppr超能文献

《视网膜色素变性的临床和康复管理:最新进展》。

Clinical and Rehabilitative Management of Retinitis Pigmentosa: Up-to-Date.

机构信息

Department of Ophthalmology, University of Ferrara, Ferrara, Italy.

出版信息

Curr Genomics. 2011 Jun;12(4):250-9. doi: 10.2174/138920211795860125.

Abstract

The term retinitis pigmentosa (RP) indicates a heterogeneous group of genetic rare ocular diseases in which either rods or cones are prevalently damaged. RP represents the most common hereditary cause of blindness in people from 20 to 60 years old. In general, the different RP forms consist of progressive photo-receptorial neuro-degenerations, which are characterized by variable visual disabilities and considerable socio-sanitary burden. Sometimes, RP patients do not become visually impaired or legally blind until their 40-50 years of age and/or maintain a quite acceptable sight for all their life. Other individuals with RP become completely blind very early or in middle childhood. Although there is no treatment that can effectively cure RP, in some case-series the disease's progression seems to be reducible by specific preventive approaches. In the most part of RP patients, the quality of vision can be considerably increased by means of nanometer-controlled filters. In the present review, the main aspects of the routine clinical and rehabilitative managements for RP patients are described, particularly focusing on the importance of specific referral Centers to practice a real multidisciplinary governance of these dramatic diseases.

摘要

视网膜色素变性(RP)是一组异质性的遗传性罕见眼病,主要累及视杆细胞或视锥细胞。RP 是 20 至 60 岁人群中最常见的致盲遗传性眼病。一般来说,不同类型的 RP 均表现为进行性光感受器神经退行性变,其特征为视力障碍的程度不同,给社会带来的负担也不同。有些 RP 患者直到 40 至 50 岁才出现视力损害或法定失明,或者终生保持相当好的视力。其他患者则在童年中期或更早失明。虽然目前尚无有效的治疗方法,但在某些病例系列研究中,特定的预防措施似乎可以减缓疾病的进展。在大多数 RP 患者中,纳米级控制滤光器可以显著提高视力质量。本文主要描述了 RP 患者的常规临床和康复管理的主要方面,尤其强调了建立专门转诊中心的重要性,以便对这些严重疾病进行真正的多学科管理。

相似文献

1
Clinical and Rehabilitative Management of Retinitis Pigmentosa: Up-to-Date.
Curr Genomics. 2011 Jun;12(4):250-9. doi: 10.2174/138920211795860125.
2
Good epidemiologic practice in retinitis pigmentosa: from phenotyping to biobanking.
Curr Genomics. 2011 Jun;12(4):260-6. doi: 10.2174/138920211795860071.
3
[Early therapeutic trials for retinitis pigmentosa].
Bull Acad Natl Med. 2003;187(9):1685-92; discussion 1692-4.
5
Retinitis Pigmentosa: Pathogenesis, Diagnostic Findings, and Treatment.
Cureus. 2023 Oct 30;15(10):e48006. doi: 10.7759/cureus.48006. eCollection 2023 Oct.
6
Retinitis Pigmentosa and Other Dystrophies.
Dev Ophthalmol. 2017;58:191-201. doi: 10.1159/000455281. Epub 2017 Mar 28.
7
Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives.
Prog Retin Eye Res. 2018 Mar;63:107-131. doi: 10.1016/j.preteyeres.2017.10.004. Epub 2017 Oct 31.
8
[Research progress of treatment strategies for retinitis pigmentosa].
Zhonghua Yan Ke Za Zhi. 2017 Feb 11;53(2):148-153. doi: 10.3760/cma.j.issn.0412-4081.2017.02.015.
9
Gene panel sequencing in Brazilian patients with retinitis pigmentosa.
Int J Retina Vitreous. 2017 Sep 11;3:33. doi: 10.1186/s40942-017-0087-6. eCollection 2017.
10
Sector retinitis pigmentosa.
Optometry. 2005 May;76(5):309-17. doi: 10.1016/s1529-1839(05)70314-6.

引用本文的文献

1
The Role of Cytokines in Degenerative Retinal Diseases: A Comprehensive Review.
Biomedicines. 2025 Jul 15;13(7):1724. doi: 10.3390/biomedicines13071724.
2
Current understanding on Retinitis Pigmentosa: a literature review.
Front Ophthalmol (Lausanne). 2025 Jun 12;5:1600283. doi: 10.3389/fopht.2025.1600283. eCollection 2025.
5
Alteration Ocular Motility in Retinitis Pigmentosa: Case-Control Study.
Clin Optom (Auckl). 2024 Feb 22;16:55-69. doi: 10.2147/OPTO.S446717. eCollection 2024.
8
Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies.
Int J Mol Sci. 2023 Apr 19;24(8):7481. doi: 10.3390/ijms24087481.
9
base editing rescues photoreceptors in a mouse model of retinitis pigmentosa.
Mol Ther Nucleic Acids. 2023 Feb 14;31:596-609. doi: 10.1016/j.omtn.2023.02.011. eCollection 2023 Mar 14.

本文引用的文献

1
Postsurgical cystoid macular edema.
Eur J Ophthalmol. 2011;21 Suppl 6:S62-8. doi: 10.5301/EJO.2010.6058.
2
Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa.
EMBO Mol Med. 2011 Mar;3(3):118-28. doi: 10.1002/emmm.201000119. Epub 2011 Jan 26.
3
Fourier-domain optical coherence tomography and microperimetry findings in retinitis pigmentosa.
Am J Ophthalmol. 2011 Jan;151(1):106-11. doi: 10.1016/j.ajo.2010.07.026. Epub 2010 Nov 20.
5
Visual field size criteria for mobility rehabilitation referral.
Optom Vis Sci. 2010 Dec;87(12):E948-57. doi: 10.1097/OPX.0b013e3181ff99be.
6
Current concepts in the treatment of retinitis pigmentosa.
J Ophthalmol. 2011;2011:753547. doi: 10.1155/2011/753547. Epub 2010 Oct 11.
7
Treatment possibilities for retinitis pigmentosa.
N Engl J Med. 2010 Oct 21;363(17):1669-71. doi: 10.1056/NEJMcibr1007685.
8
Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial.
Ophthalmologica. 2011;225(2):120-6. doi: 10.1159/000320500. Epub 2010 Oct 16.
9
Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosa.
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18706-11. doi: 10.1073/pnas.1007644107. Epub 2010 Oct 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验